Literature DB >> 20338801

Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.

Naomi De Silva1, Harold Atkins, David H Kirn, John C Bell, Caroline J Breitbach.   

Abstract

Oncolytic viruses (OVs) are selected based on their ability to eliminate malignancies by direct infection and lysis of cancer cells. Originally, OVs were designed to target malignancies by taking advantage of the defects of cancer cells observed in vitro. Subsequent analysis of virus delivery and spread in vivo has demonstrated that the tumour microenvironment can impede the ability of OVs to effectively infect and spread. Despite this limitation, it is becoming increasingly evident that OVs are also able to take advantage of certain features of the tumour microenvironment. Currently, a growing body of the literature is delineating the complex interaction between OVs and the tumour microenvironment that results in an additional therapeutic activity; these viruses are able to target malignancies by rapidly altering the tumour microenvironment into a milieu that potentiates anticancer activity. Herein, we discuss strategies that capitalize on the multifaceted relationship between OVs and host-tumour interactions that enhance the toxicity of OVs to the tumour microenvironment. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20338801     DOI: 10.1016/j.cytogfr.2010.02.007

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  15 in total

Review 1.  Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates.

Authors:  Guido Wollmann; Koray Ozduman; Anthony N van den Pol
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

Review 2.  Thunder and lightning: immunotherapy and oncolytic viruses collide.

Authors:  Alan Melcher; Kelley Parato; Cliona M Rooney; John C Bell
Journal:  Mol Ther       Date:  2011-04-19       Impact factor: 11.454

3.  Targeting tumor vasculature with an oncolytic virus.

Authors:  Caroline J Breitbach; Naomi S De Silva; Theresa J Falls; Usaf Aladl; Laura Evgin; Jennifer Paterson; Yang Yang Sun; Dominic G Roy; Julia L Rintoul; Manijeh Daneshmand; Kelley Parato; Marianne M Stanford; Brian D Lichty; Aaron Fenster; David Kirn; Harold Atkins; John C Bell
Journal:  Mol Ther       Date:  2011-03-01       Impact factor: 11.454

4.  Ex vivo infection of live tissue with oncolytic viruses.

Authors:  Jean-Simon Diallo; Dominic Roy; Hesham Abdelbary; Naomi De Silva; John C Bell
Journal:  J Vis Exp       Date:  2011-06-25       Impact factor: 1.355

5.  Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation.

Authors:  So Young Kim; Dongxu Kang; Hye Jin Choi; Yeonsoo Joo; Joo-Hang Kim; Jae J Song
Journal:  Oncotarget       Date:  2017-02-28

Review 6.  Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas.

Authors:  Qing Zhang; Fusheng Liu
Journal:  Cell Death Dis       Date:  2020-06-25       Impact factor: 8.469

Review 7.  Oncolytic virus immunotherapy: future prospects for oncology.

Authors:  Junaid Raja; Johannes M Ludwig; Scott N Gettinger; Kurt A Schalper; Hyun S Kim
Journal:  J Immunother Cancer       Date:  2018-12-04       Impact factor: 13.751

Review 8.  Targeting Tumor-Associated Antigen: A Promising CAR-T Therapeutic Strategy for Glioblastoma Treatment.

Authors:  Guidong Zhu; Qing Zhang; Junwen Zhang; Fusheng Liu
Journal:  Front Pharmacol       Date:  2021-06-24       Impact factor: 5.810

Review 9.  Advances in the design and development of oncolytic measles viruses.

Authors:  Brian Hutzen; Corey Raffel; Adam W Studebaker
Journal:  Oncolytic Virother       Date:  2015-08-27

10.  Targeting Melanoma with Cancer-Killing Viruses.

Authors:  Tiantian Zhang; Yogesh R Suryawanshi; Helene M Woyczesczyk; Karim Essani
Journal:  Open Virol J       Date:  2017-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.